

# In Memory of Kevin Robertson, PhD







# Epidemiologic/Population Research Group:

**What patient salient outcomes are most useful to gauge health related quality of life & prognosis?**

Amy C. Justice MD PhD  
Professor of Medicine and Public Health,  
Yale University  
VA Connecticut Healthcare System

## **Co-Authors**

**Matt Freiberg, Mike Silverberg,  
Keri Althoff, Kathy Anastos, Scott McClelland**

# Patient Salient Outcomes

- Reflect *quantity and/or quality* of life
- Commonly measured:
  - Mortality, hospitalization
  - HIV disease progression
  - Comorbid disease incidence, progression
- Less commonly measured, often patient reported:
  - Symptoms: pain, fatigue, sadness, nausea, diarrhea, etc.
  - Function: hearing, vision, mobility, cognition\*, mental health\*

\*covered under Topic #2

# Measurement Tools

- **Prognostic indexes** predict mortality, may predict hospitalization, falls, etc., e.g. Veterans Aging Cohort Study Index
- **Disease incidence/progression**, e.g. Framingham Risk Index or FRAX
- **Symptom** Indexes determine burden of bothersome symptoms, e.g. HIV Symptom Index
- **Health Related Quality of Life**, e.g. SF-12
- **Frailty**, e.g. Frailty Phenotype or Rockwood Score
- **Function**, e.g. timed walk, cognitive batteries, etc.

## Three Major Measurement Issues

- Want to compare aging with and without HIV
  - Metrics need to be equally valid in both groups
- Validity may differ among important subgroups
  - Gender, race, age, and resource rich vs limited settings
- If using them as outcomes in research or care
  - Responsiveness to interventions is imperative

# Key Research Questions: Prognostic Indexes

- What are the most accurate and generalizable risk indices for mortality, hospitalization, and common comorbid diseases for those aging with HIV infection:
  - Do they demonstrate similar accuracy among subgroups?
  - Are they sufficiently responsive?

# Key Research Questions: Patient Reported Outcomes

- What are the most valid & reproducible measures to study aging with HIV?
  - Do they demonstrate similar validity among subgroups?
  - Are they sufficiently responsive?



# Key Research Questions: Cross Cutting Issues

- Is frailty a useful independent concept in the study of aging with HIV? Do appropriate measures of frailty differ from those aging without HIV?
- How can useful indices of prognosis, quality of life, and frailty be integrated into routine clinical care and research?